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Abstract
Histone deacetylase inhibitors (HDACi) can induce human immunodeficiency virus (HIV) transcription from the HIV long
terminal repeat (LTR). However, ex vivo and in vivo responses to HDACi are variable and the activity of HDACi in cells other
than T-cells have not been well characterised. Here, we developed a novel assay to determine the activity of HDACi on
patient-derived HIV LTRs in different cell types. HIV LTRs from integrated virus were amplified using triple-nested Alu-PCR
from total memory CD4+ T-cells (CD45RO+) isolated from HIV-infected patients prior to and following suppressive
antiretroviral therapy. NL4-3 or patient-derived HIV LTRs were cloned into the chromatin forming episomal vector pCEP4,
and the effect of HDACi investigated in the astrocyte and epithelial cell lines SVG and HeLa, respectively. There were no
significant differences in the sequence of the HIV LTRs isolated from CD4+ T-cells prior to and after 18 months of
combination antiretroviral therapy (cART). We found that in both cell lines, the HDACi panobinostat, trichostatin A,
vorinostat and entinostat activated patient-derived HIV LTRs to similar levels seen with NL4-3 and all patient derived isolates
had similar sensitivity to maximum HDACi stimulation. We observed a marked difference in the maximum fold induction of
luciferase by HDACi in HeLa and SVG, suggesting that the effect of HDACi may be influenced by the cellular environment.
Finally, we observed significant synergy in activation of the LTR with vorinostat and the viral protein Tat. Together, our
results suggest that the LTR sequence of integrated virus is not a major determinant of a functional response to an HDACi.
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Introduction
Despite the substantial reduction in morbidity and mortality
following combination antiretroviral therapy (cART), current
treatments do not cure HIV and treatment is required life-long.
The major reason why cART cannot cure HIV is the persistence
of HIV in resting memory and naı¨ve CD4+ T-cells [1,2]. One
strategy currently being pursued to eliminate latently infected cells
is to stimulate virus production from latency [3].
Histone deacetylase inhibitors (HDACi) can activate HIV
production efficiently in nearly all latently infected cell lines [4–
9]. In contrast, in primary CD4+ T-cell models of latency, the
capacity of an HDACi to activate virus production from a latent
provirus is variable –depending on the model used [10]. Using
resting CD4+ T-cells from HIV-infected patients on cART ex vivo,
the HDACi vorinsotat induced virus production in 50–80% of
patients, in both the absence [11] or presence [8,12] of activated
feeder cells. More recently, where virus production from patient
cells was measured by RT-PCR in the absence of feeder cells,
there was minimal virus production with vorinostat compared to
the more potent HDACi romidepsin [9]. When using a reporter
cell line to measure infection, other studies have shown minimal
virus production following stimulation with all HDACi relative to
maximal stimulation with a mitogen such as PMA and ionomycin
[13]. Finally, when vorinostat and panobinostat were given to
HIV-infected patients on ART, a variable response in activation of
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latent HIV has been observed in multiple studies [12,14,15].
Taken together these studies demonstrate a far more variable
response of patient derived cells to treatment with HDACi ex vivo
compared to models that are infected with laboratory strains of
HIV.
It is likely that latent proviruses in vivo, may have variable
sensitivity to stimulation with an HDACi. Factors such as sequence
of the HIV LTR, the surrounding chromatin environment, the
specific integration site or the cellular environment may all
potentially play a role. Here, we found that the HIV LTR
sequence isolated from T cells was not a factor in determining an
ex vivo response to HDACi but that the capacity of an HDACi in
inducing HIV transcription was dependent on the cell type
examined with maximal LTR transcription observed in an
epithelial cell line. Finally, the potency of the HDACi vorinostat
was significantly enhanced in the presence of the viral protein Tat.
Materials and Methods
Patient recruitment
HIV-infected, cART naı¨ve patients (n = 4) who were initiating
cART were recruited at the Alfred Hospital, Melbourne. This was
a sub-study of a previously reported prospective observational
study [2]. Fifty millilitres of blood were collected at baseline and at
6, 12, 18, 24, and up to 60 months after initiation of cART. The
parent study and sub-study were both approved by the Alfred
hospital ethics committee (114/05) and written informed consent
was obtained from all participants.
Isolation of the integrated HIV LTR from CD4+ T-cells
Total memory T-cells from HIV-infected patients, defined as
CD4+CD45RO+CD28+, were isolated by flow cytometry sorting
using anti-CD4-fluorescein isothiocyanate (FITC), anti-CD28-PE-
cyanine dye (Cy5) and anti-CD45RO-allophycocyanin (APC;
Becton Dickinson, San Jose, CA). Cells were lysed for PCR
analysis using PCR lysis buffer (0.002% Triton X100, 0.002%
SDS, 100 mM Tris.HCl (pH 8), 1 mM EDTA with freshly added
Proteinase K 0.8 mg/ml). The DNA lysate was serially diluted
using 1 in 10 dilutions and between 12 and 24 replicates from each
dilution were added to a first round PCR mix containing 0.2 mM
of Alu1, Alu2 and 59LTRf2 primers (Table 1) in ImmoMix PCR
premix (Bioline, London, UK). The PCR was performed using
conditions described in Table 1. Two microliters of the first-round
product were then added to a second-round PCR mix containing
0.2 mM 59LTRf2 and 39nLTR#2 primers in ImmoMix PCR
premix (Table 1). Subsequently, two microliters of the second-
round product were then added to a third-round PCR mix
containing 0.2 mM 59KpnI-LTRf3 and 39nLTR#3 primers in
ImmoMix PCR premix (Table 1). The resulting products of the
first round PCR were Alu-LTR, LTR-Alu, Alu-Alu with varying
length, depending on the distance of the integrated LTR to the
closest Alu. The second and third round PCRs then preferentially
amplify the integrated LTR sequence. PCR products were
analysed by 1% agarose gel electrophoresis. The dilution that
yielded a PCR product in ,30% of replicates, was assumed to
contain one amplifiable template per reaction more than 80% of
the time, according to a Poisson distribution [16]. Using ACH2
cells (NIH AIDS Reagent Program [17]), a T-cell line that
contains a single integrated copy of HIV, we determined that the
lower limit of detection was,2 copies of HIV DNA per well. PCR
products were sequenced and hypermutated LTRs (G-.A) were
identified using the software Hypermut (http://www.hiv.lanl.gov/
content/sequence/HYPERMUT/hypermut.html). Hypermu-
tated LTRs were removed from further analyses. A phylogenetic
tree was constructed using the neighbour-joining method with
CLC Workbench software (Version 6, CLC Bio, Aarhus, Den-
mark), with bootstrapping resampling done with 100 replicates.
The consensus NL4-3 sequence was used for comparison with
patient samples.
Cells lines and cytotoxicity assay
The SVG astrocyte cell line [18] was cultured in Minimum
Essential Medium (MEM) with Earle’s salts supplemented with
10% heat-inactivated fetal bovine serum (HI-FBS), 16 penicillin-
streptomycin-glutamine (PSG) (Invitrogen, Carlsbad, CA). The
HeLa cell line (ATCC) was cultured in MEM containing 10% HI-
FBS and 16 PSG.
Table 1. Primers and triple-nested Alu-LTR-PCR conditions.
Primer Sequence PCR Condition
Round 1 Alu1 TCCCAGCTACTGGGGAGGCTGAGG 94uC for 10 minutes, 20 cycles of
(94uC for 15 seconds, 56uC for 15
seconds and 72uC for 2 minutes),




Round 2 59LTRf2 GCCACTTTTTAAAAGAAAAGGGGGACT 94uC for 10 minutes, 35 cycles of
(94uC for 15 seconds, 51uC for 15
seconds and 72uC for 1 minutes),
final extension at 72uC for
7 minutes
39nLTR#2 AAAAGGGTCTGAGGGATCTCT
Round 3 59KpnI-LTRf3 GGGGTACCAAAGGGGGACTGAAGGGCTAATTC 94uC for 10 minutes, 35 cycles of
(94uC for 15 seconds, 52uC for 15
seconds and 72uC for 1 minutes),
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Each cell line was treated with varying concentrations of
trichostatin A (TSA; Sigma), vorinostat [suberoylhydroxamic acid
(SAHA)], panobinostat (LBH589) and entinostat (MS-275; all
from Selleck Chemicals, Houston, TX) for 24 hours and toxicity
was assessed with the MTS colorimetric assay according to
manufacturer’s instructions (Promega, Madison, WI). Experiments
were performed in triplicate and the cytotoxic concentration 50
(CC50) values were generated using GraphPad Prism software
(Version 6, Graphpad, La Jolla, CA).
Cloning of HIV LTR into pCEP4
The plasmid pCEP4 (Invitrogen) was digested with SalI (NEB
Biolabs, Ipswich, MA) to remove the entire existing promoter
region, the multiple cloning site and the SV40 poly A sequence
(Fig 1). The plasmid was then blunt ended and a fragment of the
D-57/-4 HIV [19] LTR-pGL3 plasmid spanning the entire LTR
and including the luciferase gene [20] was digested with Acc65I/
BamHI and cloned into pCEP4. To clone the patient LTRs into
pCEP4, patient-derived LTRs and the D-57/-4 HIV LTR-pCEP4
vector were both digested with Acc65I and HindIII according to
the manufacturer’s instructions (NEB Biolabs). The digested LTRs
and pCEP4 vector were ligated using T4 DNA Ligase (NEB
Biolabs). Correctly inserted clones were initially screened by
colony-PCR and later confirmed by restriction digest using SalI
(NEB Biolabs).
The pCEP4 plasmid contains an Epstein-Barr virus nuclear
antigen protein (EBNA-1) to allow for extrachromosomal replica-
tion in mammalian cells [21]. Importantly, any genes cloned into
pCEP4 are susceptible to post-transcriptional modifications such
as methylation [21,22], which is important for our study.
Transfection of cells with pCEP4
HeLa (3,000 cells/well) or SVG (5,000 cells/well) cells were
seeded overnight into a 96-well flat-bottom plate. The following
day, media was replaced with 100 mL of cell media without
antibiotics and transfected with 50 mL of pre-mixed Lipofectamine
2000 (Invitrogen) contain 200 ng/well of patient-derived or NL4-3
LTR-pCEP4 according to the manufacturer’s instructions (Invi-
trogen). In some experiments, cells were also co-transfected with
4 ng/well of pTargeT-HxB2-Tat vector [20]. After 4 hours, cell
culture media was replaced with fresh culture media containing
antibiotics and incubated for another 20 hours. Subsequently,
various doses of panobinostat, trichostatin A, vorinostat and
entinostat; or phorbyl myristoacetate (PMA [20 ng/ml]; Sigma St.
Louis, MO) were added for 24 hours. Cells were then lysed in 16
Luciferase Assay Buffer (Promega, Madison, WI) and the
transcriptional activity of the LTR was measured by quantifying
luciferase expression using the Luciferase Assay System (Promega)
according to manufacturer’s instructions. Luminescence was
measured using a FLUOStar Optima microplate reader (BMG
Labtech, Ortenberg, Germany).
To determine the transfection efficiency, HeLa or SVG were
transfected as above with pEGFP-N1 (Clontech, Mountain View,
CA), a GFP-expressing plasmid, and the percentage of cells
expressing GFP was analysed 24 hours after transfection.
Quantification of HDAC proteins
To determine the expression level of HDAC 1, 2, 3 and 4
proteins in HeLa and SVG, five million cells were lysed in RIPA
lysis buffer (Thermo Scientific, Rockford, IL), containing 1% Halt
protease inhibitor cocktail (Thermo Scientific). Protein concentra-
tion was determined using a Bradford protein assay (Bio-Rad,
Hercules, CA). Twenty microgram of total proteins were loaded
onto a 10% SDS PAGE, transferred onto a PVDF membrane and
sequentially probed with rabbit anti-HDAC1, 2 and 4 and goat
anti-HDAC3 (Santa Cruz Biotechnology, Dallas, TX). HDAC
proteins were detected using Alexa Fluor 680-conjugated goat
anti-rabbit or donkey anti-goat secondary antibodies (Cell
Signaling Technology, Danvers, MA) and imaged on an Odyssey
fluorescent reader (LI-COR, Lincoln, NE).
Statistical analysis
The potency of HDACi in each cell line was analysed using one-
way analysis of variance (ANOVA) with Tukey post-test. The
potency of HDACi between different cell lines was measured using
a Student’s t-test. The synergistic effects of vorinostat with PMA or
Tat co-transfection was analysed using a Student’s t-test where the
combined effect of vorinostat + PMA or vorinostat + Tat was
compared to the sum effect of the individual treatments
(GraphPad Prism 6, LA Jolla, CA).
Results
HIV LTRs sequences isolated from memory CD4+ T-cells
show no significant changes following cART
To investigate whether there was selection or evolution of the
HIV LTR following suppressive cART, integrated HIV LTR from
memory CD4+ T-cells from HIV infected patients prior to and
after suppressive cART were cloned and sequenced. The clinical
details of these patients (n = 4) are summarised in Table 2.
Sequence analysis of the integrated HIV LTRs showed no
compartmentalisation between viral sequences in memory CD4+
T-cells prior to and following 18–24 months (Fig 2, P4–6) or up to
60 months of suppressive cART (Fig 2, P1).
Patient-derived HIV LTRs are responsive to reactivation
by all HDACi
To characterise the ex vivo response of patient derived HIV
LTR to HDACi, we first determined the cytotoxicity of each
HDACi in each cell line. In the SVG astrocyte cell line,
cytotoxicity assays showed that the HDACi panobinostat (CC50:
77 nM) was the most toxic followed by trichostatin A (CC50:
482 nM), entinostat (CC50: ,5296 nM) and vorinostat (CC50:
6864 nM) (Fig 3A–I).
We then determined the dose response of individual HDACi on
the HIV LTR using the pCEP4 plasmid that contained wild-type
NL4-3 LTR. The pCEP4 plasmid forms a mini chromatin
structure following transfection [23], which does not integrate into
the host genome. This approach therefore allowed us to examine
the effects of HDACi independent of integration site.
Following transfection of NL4-3 LTR-pCEP4 into SVG cells
and treatment with various doses of HDACi, we quantified
luciferase activity. Treatment with PMA (20 ng/ml) and co-
transfection with Tat (4 ng) were used as positive controls and
induced an increase in luciferase activity of 2.360.3 and a 45.061
fold above the media-treated sample, respectively. Panobinostat
(50 nM), trichostatin A (250 nM), vorinostat (5 mM) and entinostat
(5 mM) induced an increase in luciferase activity above the media-
treated sample of 17.462.6, 17.763.3, 25.861.7 and 26.863.2
fold respectively (Fig 3A–II; n = 3). These concentrations of
HDACi were used in subsequent experiments in SVG as they
were shown to induce the maximal response from NL4-3 LTR-
pCEP4 but were below the CC50 value.
Patient-derived LTRs isolated prior to and following cART
were ligated into pCEP4 as described above. We found that the
patient derived LTRs had similar sensitivity to HDACi as seen
with NL4-3 LTR-pCEP4 with a mean 6 SE fold increase in
luciferase above untreated control following panobinostat
HDACi Induced HIV LTR Transcription Ex Vivo
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(23.862.7), trichostatin A (22.460.8), vorinostat (26.463) and
entinostat (25.963.9) (Fig 3A–III, n = 9). There was no significant
difference in the maximum fold luciferase induction between
HDACi at the concentrations tested. LTRs derived from patients
while on suppressive cART were also sensitive to reactivation by
all HDACi (Fig 3A–III). To confirm that we were not missing
subtle differences between patient-derived LTRs following stim-
ulation with lower concentration of HDACi rather than maximal
stimulation, we also evaluated the response of three patient derived
LTRs to a wide range of HDACi concentrations and again found
no significant differences between the patient derived LTRs which
all had similar EC50 to the wild type LTR (Figure S1).
Most LTRs showed a greater responsiveness to Tat than to
treatment with HDACi (range 2.2-160 fold above untreated
control). We identified one clone that was highly sensitive to
reactivation by Tat (P4BL1) and a clone that was resistant to Tat-
mediated transactivation (P6BL6). There were no obvious
mutations of the LTR at the NF-kB, SP1 or TATA sites [24,25]
that may have rendered this clone resistant to tat-mediated
transactivation.
Figure 1. Cloning of patient-derived HIV LTRs into pCEP4. (A) Total memory T cells from HIV-infected individuals were isolated from blood
collected prior to or after receiving cART. The integrated HIV LTRs from these cells were isolated by triple nested Alu-LTR PCR. (B)(I) The plasmid
pCEP4 was digested with SalI to remove the entire PCMV promoter region and the SV40 poly A sequences. (II) DNA sequence of the D-57/-4 HIV LTR
and the luciferase gene was generated by digestion of the D-57/-4 LTR pGL3-Basic vector [20] and ligated into pCEP4. (III) Patient-derived HIV LTRs
were cloned into the D-57/-4 LTR-pCEP4 vector using the Acc65I and HindIII sites. (IV) Patient LTR pCEP4 was transfected into SVG and HeLa cell lines;
the activity of various HDACi on LTR transcription was measured by quantification of luciferase activity.
doi:10.1371/journal.pone.0113341.g001
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The same experiments were then performed in HeLa cells
(Fig 3B–I to III) where the CC50 for each HDACi was similar to
what we found with SVG (Fig 3B–I). In the HeLa cell line, the
maximal fold induction of luciferase from patient-derived LTRs
(n = 4) by panobinostat (622635 fold increase) and vorinostat
(660659 fold increase) were significantly greater compared to
trichostatin A (288637 fold increase; p= 0.004), but was not
significantly greater than entinostat (5226 fold increase) (Fig 3B–
III).
Significantly greater response of the HIV LTR to HDACi in
the HeLa compared to SVG cell lines
We observed similar levels of luciferase in HeLa compared to
SVG following stimulation with Tat (approximately a 40 fold
increase) but significantly higher levels of luciferase activity
following stimulation by each of the HDACi in HeLa (Fig 3C).
The differences in the maximum fold induction of HDACi in SVG
and HeLa cells were unlikely to be attributed to the expression of
the HDAC proteins 1–4 which were similar in the two cell lines
(Figure S2A) or efficiency of transfection given that we observed
similar transfection efficiency in both cell types when using an
expressed green fluorescent protein (GFP) reporter plasmid (Figure
S2B).
Vorinostat synergises with Tat to increase transcription of
HIV LTRs
Given that the transactivation activity of Tat is tightly regulated
by post-translational modification such as acetylation and meth-
ylation [26–28], we next investigated whether there was a
synergistic response of the LTR to Tat and an HDACi. Using
NL4-3 LTR-pCEP4 transfected into the SVG cell line, we showed
that vorinostat significantly enhanced the transactivation activity
of Tat by up to 2.7 fold (Fig 4A). This synergistic effect was also
observed using two patient-derived LTRs (P4T3 and P5T4, n= 3).
Figure 2. Phylogenetic analyses of DNA sequences derived from integrated virus in CD4+ memory T-cells. Phylogenetic trees were
constructed using a neighbour-joining method with sequences from nucleotide 6 to 548 of the LTR derived from memory CD4+ T-cells prior to the
initiation of cART (open symbols), after at least 18 months of cART (closed symbols) in four participants and the consensus sequence from NL4-3
(square symbol). Arrows indicate clones selected at random for cloning into pCEP4. Scale-bars indicate genetic distance (e.g., 0.01 = 1% genetic
distance). Bootstrap values of .75 are shown on branches. All hypermutated clones (P,0.05 analysed on Hypermut V2.0) were excluded from the
analysis.
doi:10.1371/journal.pone.0113341.g002
Table 2. Patient characteristics.
Patient ID Age* (yrs) Study sample (time on ART) VL (RNA copies/ml) CD4 count (cell/ml)
P1 43 BL 3700 27
(60 months) ,50 183
P4 71 BL 100000 71
(18 months) ,50 397
P5 41 BL 100000 118
(24 months) ,50 792
P6 41 BL 71700 129
(18 months) ,50 297
BL, Baseline; VL, viral load in plasma; * age at recruitment ie BL.
doi:10.1371/journal.pone.0113341.t002
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We also investigated the effects of HDACi on APOBEC3G
induced hypermutated LTRs (defined as a G to A mutation [29])
given that up to,1/3 of noninduced proviruses are hypermutated
[30]. Despite failing to be activated by Tat alone, these
hypermutated sequences were sensitive to reactivation by vorino-
stat (Fig 4B) and co-stimulation of cells with vorinostat and Tat
significantly enhanced the level of luciferase production by up to
7.3-fold (Fig 4B, n = 3).
Finally, given that previous studies have shown that HDACi
synergise with prostratin (an NF-kB/PKC activator [31,32]); we
wanted to determine whether this synergism could be demon-
strated in this model. Using PMA to activate PKC, we showed that
vorinostat and PMA increased the transcriptional activity of NL4-
3 LTR-pCEP4 by 1.5 fold (Fig 4C); however, there was no
significant synergism between HDACi and PMA using patient-
derived HIV LTRs in this model.
Discussion
HDACi are now being evaluated in HIV-infected patients on
suppressive cART as a strategy to eliminate latently infected cells.
The response of resting CD4+ T-cells from HIV-infected patients
on cART to HDACi stimulation is variable both in vivo and ex
vivo but the mechanism for this variable response is currently
unclear. Here we demonstrate that the HDACi panobinostat,
trichostatin A, vorinostat and entinostat can induce transcription
from the majority of HIV LTRs isolated from memory CD4+ T-
cells from HIV-infected patients on suppressive cART. Further-
more, there were no differences in response to HDACi from HIV
LTRs isolated from patients prior to or after treatment with
cART. The main factor that determined the magnitude of
response to HDACi stimulation was the cellular environment
with a maximal fold induction of luciferase observed in the HeLa
cell line.
Figure 3. Ex vivo response of patient-derived HIV LTRs to HDACi in A. SVG and B. HeLa cell lines. (I) Each cell line was incubated with
different concentrations of HDACi for 24 hr and toxicity was measured by the MTS assay. The cytotoxic concentration 50 (CC50) for each drug is
shown. (II) SVG or HeLa cells were transiently transfected with the wild-type NL4-3 LTR- pCEP4 and treated with various concentrations of HDACi for
24 hr. Co-transfection with Tat (4 ng) or incubation with PMA (20 nM) were used as positive controls. The activity of the LTR was measured as the fold
change in luciferase compared to the untreated sample. # indicates doses of individual HDACi that were closest to the CC50 and induced the largest
fold change increase in luciferase activity. (III) Luciferase expression following transfection of pCEP4 containing LTR sequences isolated from total
memory CD4+ T-cells prior to or after cART and treated with the optimal dose of HDACi. (C) Comparison of the luciferase expression in HeLa (red) and
SVG (blue) following transfection of pCEP4 containing LTR sequences from (B III) and treated with the optimal dose of HDACi. Boxes represent the
median, 25th and 75th percentiles and error bars the 10th and 90th percentiles. Ns = not statistically significant.
doi:10.1371/journal.pone.0113341.g003
HDACi Induced HIV LTR Transcription Ex Vivo
PLOS ONE | www.plosone.org 6 November 2014 | Volume 9 | Issue 11 | e113341
HDACi are subdivided into different classes based on their
biochemical structure. Trichostatin A and panobinostat are both
hydroxamic acids, whereas vorinostat is a suberoylanilide hydro-
xamic acid and entinostat is a benzamide derivative [3,33,34].
Slight differences in the chemical structure of the various HDACi
may affect the way they interact with host histone acetyltransfer-
ases and transcription factors. Additionally, panobinostat, trichos-
tatin A and vorinostat are pan-HDACi, whilst entinostat
specifically inhibits HDAC1 and 3 [35]. We showed that both
vorinostat and panobinostat induced a similar magnitude of
luciferase expression when tested at concentrations below the
CC50. However, panobinostat was substantially more potent (.
100 fold) as described in multiple previous studies using CD4+ T-
cells from HIV-infected patients on cART [13,36], a primary T-
Figure 4. Vorinostat synergises with Tat and not PMA to increase transcription of the HIV LTR. SVG cells were transiently transfected
with pCEP4 plasmid containing either NL4-3 or patient-derived HIV LTRs and luciferase activity was quantified following treatment with vorinostat
(5 mM) and co-transfection with Tat using (A) non-mutated or (B) hypermutated (P,0.05 analysed on Hypermut V2.0) patient-derived HIV LTRs. (C)
luciferase activity was quantified following stimulation of non-mutated patient-derived LTRs with vorinostat and PMA (20 ng/ml). Error bars represent
standard error of the mean of three independent experiments. * P,0.05, ** P,0.01 and *** P,0.001. ns = not statistically significant.
doi:10.1371/journal.pone.0113341.g004
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cell model of HIV latency [36,37] or latently infected cell lines
[38], which all showed a significantly lower EC50 of panobinostat
compared to vorinostat. The maximum fold response, using
concentrations of HDACi that were within the therapeutic range
in vivo [39] was clearly not dependent on the sequence of the
LTR.
The maximum fold increase in luciferase expression induced by
HDACi varied significantly between the two cell lines tested, even
though there were similar responses to Tat. The differences in
response to HDACi between these cell lines were not explained by
differential expression of HDACs in these cells or transfection
efficiency (Figure S2). The SVG cell line was originally derived
from a primary glial cell that is less activated and has lower
replication rate and capacity [18] compared to the HeLa cell, a
cervical cancer cell, which has a doubling time of approximately
18–24 hours [40]. As most transcription factors are increased in
replicating cells or with activation [41], one might expect the
transcriptional activity of an SVG to be lower than HeLa, which
was indeed what we observed. It is also possible that these two cell
lines may differ in other key factors required for transcription of
HIV including recruitment of HDAC and histone acetyltransfer-
ases to the LTR, and/or the concentration of critical proteins such
as positive transcription elongation factor b (P-TEFb) and its
association with the inhibitory complex comprising of HEXIM1
and 7SK snRNP [31,42–44]. Phosphorylation of P-TEFb by
vorinostat has recently been demonstrated and may also differ
between the two cell lines tested in this study [45].
We observed clear synergy between Tat and the HDACi
vorinostat – even with LTR sequences that had minimal
responsiveness to Tat alone. The activity of Tat is tightly regulated
by post-translation modification processes such as acetylation
specifically at lysine 28 (K28) and K50/52 [26,27,46]. It is possible
that vorinostat is capable of modifying Tat’s function via
acetylation of these key residues. Indeed, synergism between
trichostatin A and Tat has previously been reported, and was
dependent on lysine residues at K28 and K50 [46]. This
synergistic interaction with Tat should be further exploited to
increase the activity of HDACi in driving HIV transcription.
Finally, we found that all HDACi tested in this study could
activate transcription from the HIV LTRs even when there was
evidence of hypermutation. Although these hypermutated LTRs
are unlikely to contribute to production of replication competent
virus [29], the fact that these hypermutants were sensitive to
reactivation by a HDACi could be of biological significance
especially if protein produced from these viruses could also
stimulate HIV-specific T-cells responses [9].
This is the first study to evaluate the effectiveness of HDACi to
activate patient derived LTR sequences ex vivo in cells other than
T cells. The study highlights the impact of the cellular
environment on the ability of HDACi to activate transcription
and is important for understanding the use of HDACi in cure
strategies. However our approach has several limitations. First, the
pCEP system although forming mini chromatin, doesn’t integrate
into the host genome. It is possible that the nucleosome positioning
of these LTRs may therefore be different to what has been
observed in HIV-infected cells from patients. However, we believe
there are several reasons to expect they would be similar. First, our
patient-derived LTR-pCEP4 constructs included all the sequences
normally required for integration and nucleosome positioning
[47]. Second, it has been shown that nuc-0, 1, 2 are strictly formed
at specific positions regardless of the site of virus integration in the
host gene [47,48], suggesting it is the sequence of the LTR that
confer nucleosome formation and not the surrounding host or
plasmid sequences. However, we recognise that the epigenetic
environment of host DNA will also influence the activity of
HDACi in vivo and the use of an integrating vector with patient
derived LTRs would be of interest. These experiments are
currently being performed.
In conclusion, we have developed an ex vivo model to assess the
response of patient derived LTRs to different HDACi. We have
shown that changes in the HIV LTR sequence did not translate
into differences in sensitivity to activation of transcription by an
HDACi. Using concentrations of HDACi close to the CC50,
similar maximum fold activation was observed for a panel of
HDACi. Therefore, we propose that other factors such as the site
of integration and the surrounding epigenetic environment are
likely to be relevant in determining the variable response of
latently infected cells to stimulation with an HDACi.
Supporting Information
Figure S1 Dose response of HDACi on the activity of
patient-derived HIV LTRs. HeLa cells was transiently
transfected with three patient-derived LTR-pCEP4 and treated
with various concentrations of HDACi for 24 hours. The activity
of the LTR was measured as the fold change in luciferase
compared to the untreated sample. All patient-LTRs produced a
similar pattern of response to HDACi compared with the NL4-3
LTR from Figure 3A-II. Error bars represent standard deviation
of two independent experiments.
(TIF)
Figure S2 Expression of HDACs proteins and transfec-
tion efficiency of HeLa and SVG cells. (A) Total cell lysate
(20 mg) from HeLa and SVG were probed with antibodies to
HDAC1, 2, 3 and 4 and detected by Western blotting. GAPDH
was used as a control for equal protein loading. (B) HeLa (left) and
SVG cells (right) were transfected with a GFP-expressing plasmid
(solid line) or control plasmid (broken line) for 24 hours and
expression of GFP was analysed by flow cytometry. Histogram is a
representative of two experiments with similar GFP expression.
(TIF)
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